Stakeholders.

<p>A simplified, schematic overview of stakeholders and relationships in the pharmaceutical market. Own work.</p

PRISMA flow chart.

<p>Schematic overview of the study selection process. FT: Financial Times, NYT: New York Times, WSJ: Wall Street Journal</p

Drug life cycle curve.

<p>General curve describing an innovator drug’s investments and earnings during R&D and market performance. The life cycle phases are indicated above the graph, and the phases of the R&D trajectory are below the graph. Own work.</p

Overview of the evidence for involved brain areas.

<p>PET: Positron Emission Tomography, EEG: Electroencephalography, (f)MRI: (functional) Magnetic Resonance Imaging, SPECT: Single-photon emission computed tomography, ERP: event-related potentials, CT: computed tomography.</p><p>Overview of the evidence for involved brain areas.</p

Overview of the evidence for involved prenatal environmental factors.

<p>Overview of the evidence for involved prenatal environmental factors.</p

Overview of the evidence for genetic influences.

<p>For a more complete overview, see Vassos’ review <a href="http://www.plosone.org/article/info:doi/10.1371/journal.pone.0110672#pone.0110672-Vassos1" target="_blank">[76]</a>.</p><p>Overview of the evidence for genetic influences.</p

Selection of publications.

<p>Out of the 3508 found articles, 126 were used for this article.</p

Overview of the evidence for environmental factors.

<p>Overview of the evidence for environmental factors.</p

Overview of the evidence for involved neurotransmitters and hormones.

<p>GABA : γ-aminobutyric acid, T3: triodothyronine.</p><p>Overview of the evidence for involved neurotransmitters and hormones.</p

Antidepressant use in the NL and the UK (SSRIs, TCAs, and other antidepressants) (A), segmentation of SSRI use in the NL (B), and in the UK (C).

<p>Dotted lines represent a change in use trend and therefore a new, or the end of a segment. *The grey periods represent the periods of media coverage of regulatory warnings.</p